Effects of a Novel Cardioselective ATP-Sensitive Potassium Channel Antagonist, 1-[[5-[2-(5-Chloro-o-anisamido)ethyl]-beta-methoxyethoxyphenyl]s ulfonyl]-3-methylthiourea, Sodium Salt (HMR 1402), on Susceptibility to Ventricular Fibrillation Induced by Myocardial Ischemia: In Vitro and in Vivo Studies